Wortmannin inhibits proliferation and induces apoptosis of MCF-7 breast cancer cells

Objective: The present study aimed to explore the effects of wortmannin in the proliferation and apoptosis of human breast cancer MCF-7 cells. Methods: The authors treated cells with 0, 1, 6.25, 12.5, 25, and 50 nM wortmannin for 24, 48, and 72 hours. Inhibition of proliferation was measured by cell counting kit-8 assay (CCK8). Apoptosis was detected with Annexin V-fluorescein isothiocyanate/propidium iodide double staining by flow cytometry. Additionally, expression of proteins involved in the PI3K pathway, specifically total Akt, phasphorylated Akt (p-Akt), and NF-kappa B was detected by Western blotting following 24 hours of wortmannin exposure. Results: Higher doses (6.25, 12.5, 25, and 50 nM) of wortmannin significantly inhibited proliferation of MCF-7 cells after 24, 48, and 72 hours of exposure compared with control MCF-7 cells incubated with DMSO alone in DMEM (p < 0.05). This inhibition increased with concentration and duration of treatment. Similarly, wortmannin at 6.25, 12.5, 25, and 50 nM concentrations significantly increased apoptosis of MCF-7 cells following 24 hours of exposure (p < 0.05). Western blotting revealed that increasing concentrations of wortmannin (6.25, 12.5, 25, and 50 nM, 24 hours) increasingly reduced expression of p-Akt and NF-kappa B; however, expression of total Akt was unaffected at any concentration of wortmannin. Conclusions: Wortmannin inhibits proliferation and induces apoptosis of MCF-7 cells in a dose and time-dependent manner, likely through down-regulation of PI3K/Akt signaling and NF-kappa B protein expression.

Wortmannin; MCF-7 cell line; Proliferation; Apoptosis; PI3K/Akt

[1] Huang X.L., Cui G.H., Zhou K.Y.: “Correlation of PI3K-Akt signal pathway to apoptosis of tumor cells”. Ai Zheng, 2008, 27, 331.

[2] Wu C., Huang J.: “Phosphatidylinositol 3-kinase/AKT mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer”. J. Biol. Chem., 2007, 282, 3571.

[3] Carnero A.: “The PKB/AKT pathway in cancer”. Curr. Pharm. Des., 2010, 16, 34.

[4] Wipf P., Halter R.J.: “Chemistry and biology of wortmannin”. Org. Biomol. Chem., 2005, 3, 2053.

[5] Hazeki O.: “Wortmannin, an inhibitor of phosphatidylinositol 3-kinase”. Seikagaku, 1995, 67, 33.

[6] Isbarn H., Budäus L., Pichlmeier U., Conrad S., Huland H., Friedrich M.G.: “Comparison of the effectiveness between longterm instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with nonmuscle-invasive urothelial cancer of the urinary bladder”. Urologe A., 2008, 47, 608.

[7] Zhang T., Cui G.B., Zhang J., Zhang F., Zhou Y.A., Jiang T. et al.: “Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation”. Oncol. Rep., 2010, 24, 1683.

[8] Yan J., Xu Y.H.: “Tributyrin inhibits human gastric cancer SGC-7901 cell growth by inducing apoptosis and DNA synthesis arrest”. World J. Gastroenterol., 2003, 9, 660.

[9] Zhang D., Fan D.: “Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges”. Exp. Rev. Anticancer. Ther., 2007, 7, 1369.

[10] Bartholomeusz C., Gonzalez-Angulo A.M.: “Targeting the PI3K signaling pathway in cancer therapy”. Exp. Opin. Ther. Targets, 2012, 16, 121.

[11] Sliva D.: “Signaling pathways responsible for cancer cell invasion as targets for cancer therapy”. Curr. Cancer Drug. Targets, 2004, 4, 327.

[12] Polak R., Buitenhuis M.: “The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia”. Blood, 2011, 24, 1666.

[13] Han Z., Hong L., Han Y., Wu K., Han S., Shen H. et al.: “Phospho- Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gP, Bcl-2 and Bax”. J. Exp. Clin. Cancer Res., 2007, 26, 261.

[14] Lee C.H., Jeon Y.T., Kim S.H., Song Y.S.: “NF-kappaB as a potential molecular target for cancer therapy”. Biofactors, 2007, 29, 19.

[15] Ohta T., Ohmichi M., Hayasaka T., Mabuchi S., Saitoh M., Kawagoe J. et al.: “Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models”. Endocrinology, 2006, 147, 1761.

[16] Poh T.W., Pervaiz S.: “LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway”. Cancer Res., 2005, 65, 6264.